ZYUS logo

ZYUS Life Sciences Corporation Stock Price

TSXV:ZYUS Community·CA$55.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ZYUS Share Price Performance

CA$0.69
-0.15 (-17.86%)
CA$0.69
-0.15 (-17.86%)
Price CA$0.69

ZYUS Community Narratives

There are no narratives available yet.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with imperfect balance sheet.

4 Risks
0 Rewards

ZYUS Life Sciences Corporation Key Details

CA$483.0k

Revenue

CA$1.4m

Cost of Revenue

-CA$952.0k

Gross Profit

CA$33.1m

Other Expenses

-CA$34.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.43
-197.10%
-7,047.21%
-107.1%
View Full Analysis

About ZYUS

Founded
2018
Employees
n/a
CEO
Brent Zettl
WebsiteView website
www.zyus.com

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

Recent ZYUS News & Updates

Recent updates

No updates